Skip to main content
Top
Published in: European Journal of Nutrition 5/2020

01-08-2020 | Irritable Bowel Syndrome | Original Contribution

Low FODMAP diet significantly improves IBS symptoms: an Irish retrospective cohort study

Authors: Khairul Najmi Muhammad Nawawi, Mary Belov, Carol Goulding

Published in: European Journal of Nutrition | Issue 5/2020

Login to get access

Abstract

Introduction

There is growing evidence that a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) improves symptoms in irritable bowel syndrome (IBS) patients. We aimed to retrospectively investigate the effects of this diet in Irish IBS cohort over a 12-month follow-up period, including after re-introduction of the high FODMAP foods.

Methods

All the tertiary referrals seen by an FODMAP-trained dietician were reviewed (2013–2016). Patients were evaluated for IBS symptoms by a questionnaire (four-point Likert scale). Subsequently, advice regarding the low FODMAP diet was given. Symptoms’ response was assessed at 3-, 6-, and 12-month follow-up, by use of the same questionnaire. Re-introduction of high FODMAP foods was aimed to commence at the subsequent follow-up.

Results

A total of 164 patients were identified. Thirty-seven patients were excluded due to failure to attend for follow-up. Hundred and twenty-seven patients (77% patients, of which 85% were female) completed the initial 3-month follow-up. Forty-five percent (74/164) and twenty-five percent (41/164) of the patients had continued follow-up at 6 and 12 months, respectively. Of the 127 patients who returned for follow-up, their commonest baseline symptoms were lethargy (92%), bloating (91%), flatulence (91%), and abdominal pain (89%). All symptoms were significantly improved at the initial follow-up (p < 0.0001 for all). Most patients (66%) were satisfied with their overall symptoms control. In patients who had a longer follow-up duration, all symptoms remained significantly improved compared to the baseline (p < 0.0001 for combined symptoms at 6 and 12 months). After re-introduction of the high FODMAP foods, all patients maintained their symptomatic response (n = 14/14 and n = 7/7 at 6- and 12-month follow-up, respectively). The best symptoms’ improvement was seen in those who were fully adherent to the FODMAP diet.

Conclusion

In this Irish retrospective cohort study, the low FODMAP diet significantly improved all IBS symptoms at 3-, 6-, and 12-month follow-up. Following the re-introduction of the high FODMAP foods in a subgroup of patients, they were able to maintain their long-term symptomatic response up to 9 months. The low FODMAP diet might be continued for longer than 3 months; however, further studies are needed to assess the long-term safety of this diet.
Literature
1.
go back to reference Agréus L, Svärdsudd K, Nyrén O, Tibblin G (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109(3):671–680CrossRefPubMed Agréus L, Svärdsudd K, Nyrén O, Tibblin G (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109(3):671–680CrossRefPubMed
2.
go back to reference Husain N, Chaudhry IB, Jafri F, Niaz SK, Tomenson B, Creed F (2008) A population-based study of irritable bowel syndrome in a non-Western population. Neurogastroenterol Motil 20(9):1022–1029CrossRefPubMed Husain N, Chaudhry IB, Jafri F, Niaz SK, Tomenson B, Creed F (2008) A population-based study of irritable bowel syndrome in a non-Western population. Neurogastroenterol Motil 20(9):1022–1029CrossRefPubMed
3.
go back to reference Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L (2002) Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 47(1):225–235CrossRefPubMed Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L (2002) Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 47(1):225–235CrossRefPubMed
4.
go back to reference Wilson S, Roberts L, Roalfe A, Bridge P, Singh S (2004) Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 54(504):495–502PubMedPubMedCentral Wilson S, Roberts L, Roalfe A, Bridge P, Singh S (2004) Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 54(504):495–502PubMedPubMedCentral
5.
go back to reference Markowitz MA, Jhingran P, Asgharian A, Harris WA, Brod M, Wentz AL, Gordon SH, Carter E (2000) IBS prevalence: results from a community based patient registry based on the Rome II criteria. Am J Gastroenterol 95:2634CrossRef Markowitz MA, Jhingran P, Asgharian A, Harris WA, Brod M, Wentz AL, Gordon SH, Carter E (2000) IBS prevalence: results from a community based patient registry based on the Rome II criteria. Am J Gastroenterol 95:2634CrossRef
6.
go back to reference Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10(7):712–721CrossRefPubMed Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10(7):712–721CrossRefPubMed
8.
go back to reference Ford AC, Tally NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P (2008) Effect of fibre, antispasmodics and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313CrossRefPubMedPubMedCentral Ford AC, Tally NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P (2008) Effect of fibre, antispasmodics and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313CrossRefPubMedPubMedCentral
10.
go back to reference Eswaran S (2017) Low FODMAP in 2017: lessons learned from clinical trials and mechanistic studies. Neurogastroenterol Motil 29:e13055CrossRef Eswaran S (2017) Low FODMAP in 2017: lessons learned from clinical trials and mechanistic studies. Neurogastroenterol Motil 29:e13055CrossRef
12.
13.
go back to reference Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K (2012) Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142(8):1510–1518CrossRefPubMed Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K (2012) Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142(8):1510–1518CrossRefPubMed
15.
go back to reference Marsh A, Eslick EM, Eslick GD (2015) Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr 55(3):897–906CrossRefPubMed Marsh A, Eslick EM, Eslick GD (2015) Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr 55(3):897–906CrossRefPubMed
16.
go back to reference Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64:93–100CrossRefPubMed Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64:93–100CrossRefPubMed
17.
go back to reference O’Keeffe M, Jansen C, Martin L, Williams M, Seamark L, Staudacher HM, Irving PM, Whelan K, Lomer MC (2018) Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil 30(1):712–721 O’Keeffe M, Jansen C, Martin L, Williams M, Seamark L, Staudacher HM, Irving PM, Whelan K, Lomer MC (2018) Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil 30(1):712–721
18.
go back to reference Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR (2016) Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 44:447–459CrossRefPubMed Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR (2016) Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 44:447–459CrossRefPubMed
Metadata
Title
Low FODMAP diet significantly improves IBS symptoms: an Irish retrospective cohort study
Authors
Khairul Najmi Muhammad Nawawi
Mary Belov
Carol Goulding
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 5/2020
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-019-02074-6

Other articles of this Issue 5/2020

European Journal of Nutrition 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.